Podlesak Dennis 4

What Happened

• Dennis Podlesak, a director of Syndax Pharmaceuticals (SNDX), was granted 48,000 restricted stock units (RSUs) on 2026-02-04. The award was recorded at $0.00 per share (no cash paid at grant) and therefore shows $0 total consideration on the Form 4. This is an award grant (transaction code A), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-04; Form 4 filed 2026-02-06 (timely filing).
• Security: 48,000 restricted stock units (RSUs); grant price reported as $0.00.
• Shares delivered after transaction: underlying shares will not be delivered until vesting; the filing does not disclose immediate stock delivery or sale.
• Vesting/note: RSUs vest one year from the grant date. Underlying shares will not be delivered and may not be transferred or sold until the earlier of separation from service, death, disability, or a change in control.
• Transaction code: A = Award/Grant.

Context

• This is an equity award, commonly used for compensation and retention; it does not represent a cash purchase or a sale by the insider and does not indicate immediate market activity (no shares were sold or purchased on the open market).
• Because the RSUs vest in the future, they only become actual shares (and potentially sellable) if and when vesting or specified triggering events occur.